Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?

Amin Talebi Bezmin Abadi, Enzo Ierardi, Amin Talebi Bezmin Abadi, Enzo Ierardi

Abstract

Within a short time after the discovery of Helicobacter pylori, its critical role in many gastroduodenal disorders became evident. Many in vitro and in vivo data have proven that infection should be treated in order to avoid lasting colonization which may lead to problematic gastroduodenal diseases. Probiotics, preventive and therapeutic vaccines and antibiotic therapy are the main options proposed to cure these disorders. 25 years ago, triple therapy including a traditional proton pump inhibitor (PPI) and two antibiotics (amoxicillin and clarithromycin or metronidazole) was defined as the best therapy formulation for the H. pylori infection. With the strongly decreased effectiveness of this scheme, many empirical therapeutic regimens have been developed. However, the prevalence of resistance is increasing worldwide and reveals important geographic differences and even the most recent and effective regimens show some critical points. Therefore, efficacy of vonoprazan-based therapy in regions with low rate of clarithromycin resistance may be limited. In this review, we attempt to open a new window to overcome the problem of antibiotic resistance to H. pylori. In fact, we focused our attention on the possibility that conventional PPI may be replaced by vonoprazan, thus giving rise to the beginning of a new era characterized by an improved therapeutic option for H. pylori infection. Therefore, we hypothesize that switching to vonoprazan as a novel acid blocker for H. pylori treatment might allow an unexpected reassessment of the triple therapy, at least in regions with low rate of clarithromycin resistance. Nevertheless, this optimistic view of the problem could be disproved by the possible failure of vonoprazan based therapeutic regimens outside of Japan in geographic areas characterized by different rates of antibiotic resistances.

Keywords: Helicobacter pylori; PPI; therapy; treatment; vonoprazan.

Figures

FIGURE 1
FIGURE 1
Different eradication rates observed following application of vonoprazan versus conventional PPIs.

References

    1. Ashida K., Sakurai Y., Hori T., Kudou K., Nishimura A., Hiramatsu N., et al. (2016). Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment. Pharmacol. Ther. 43 240–251. 10.1111/apt.13461
    1. Chey W. D. (2012). Current consensus and remaining questions regarding the diagnosis and treatment of Helicobacter pylori Infection. Gastroenterol. Hepatol. 8 623–625.
    1. Fallone C. A., Chiba N., van Zanten S. V., Fischbach L., Gisbert J. P., Hunt R. H., et al. (2016). The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 151 51.e14–69.e14. 10.1053/j.gastro.2016.04.006
    1. Fock K. M., Katelaris P., Sugano K., Ang T. L., Hunt R., Talley N. J., et al. (2009). Second asia-pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 24 1587–1600. 10.1111/j.1440-1746.2009.05982.x
    1. Gao C. P., Zhou Z., Wang J. Z., Han S. X., Li L. P., Lu H. (2016). Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: a systematic review and meta-analysis. J. Dig. Dis. 17 811–819. 10.1111/1751-2980.12432
    1. Garnock-Jones K. P. (2015). Vonoprazan: first global approval. Drugs 75 439–443. 10.1007/s40265-015-0368-z
    1. Graham D. Y. (2016). Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut 66 384–386.
    1. Graham D. Y., Lee S.-Y. (2015). How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol. Clin. North Am. 44 537–563. 10.1016/j.gtc.2015.05.003
    1. Graham D. Y., Lee Y. C., Wu M. S. (2014). Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. 12 177.e3–86.e3. 10.1016/j.cgh.2013.05.028
    1. Hagiwara T., Mukaisho K.-I., Nakayama T., Hattori T., Sugihara H. (2015). Proton pump inhibitors and Helicobacter pylori-associated pathogenesis. Asian Pac. J Cancer Prev. 16 1315–1319. 10.7314/APJCP.2015.16.4.1315
    1. Ierardi E., Giorgio F., Losurdo G., Di Leo A., Principi M. (2013). How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J. Gastroenterol. 19 8168–8180. 10.3748/wjg.v19.i45.8168
    1. Jung Y., Kim E., Park C. (2017). Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 46 106–114. 10.1111/apt.14130
    1. Kim S. G., Jung H. K., Lee H. L., Jang J. Y., Lee H., Kim C. G., et al. (2013). Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, revised edition. J. Gastroenterol. Hepatol. 62 3–26.
    1. Lee M., Kemp J. A., Canning A., Egan C., Tataronis G., Farraye F. A. (1999). A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. Arch. Intern. Med. 159 2312–2316. 10.1001/archinte.159.19.2312
    1. Lee S. Y. (2014). [New guidelines for Helicobacter pylori treatment: comparisons between Korea and Japan]. Korean J. Gastroenterol. 63 151–157. 10.4166/kjg.2014.63.3.151
    1. Losurdo G., Giorgio F., Iannone A., Principi M., Barone M., Di Leo A., et al. (2016). Role of concomitant therapy for Helicobacter pylori eradication: a technical note. World J. Gastroenterol. 22 8638–8640. 10.3748/wjg.v22.i38.8638
    1. Malfertheiner P., Megraud F., Morain C. A., Gisbert J. P., Kuipers E. J., Axon A. T., et al. (2016). Management of ⁢em>Helicobacter pylori⁢/em> infection—the maastricht V/florence consensus report. Gut 66 6–30. 10.1136/gutjnl-2016-312288
    1. Malfertheiner P., Megraud F., O’Morain C., Bazzoli F., El-Omar E., Graham D., et al. (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 56 772–781. 10.1136/gut.2006.101634
    1. Malfertheiner P., Megraud F., O’Morain C., Gisbert J., Kuipers E., Axon A., et al. (2017). European Helicobacter and microbiota study group and consensus panel. management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 66 6–30. 10.1136/gutjnl-2016-312288
    1. Malfertheiner P., Megraud F., O’Morain C., Hungin A. P., Jones R., Axon A., et al. (2002). Current concepts in the management of Helicobacter pylori infection–the Maastricht 2-2000 consensus report. Aliment. Pharmacol. Ther. 16 167–180. 10.1046/j.1365-2036.2002.01169.x
    1. Malfertheiner P., Megraud F., O’morain C. A., Atherton J., Axon A. T., Bazzoli F., et al. (2012). Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut 61 646–664. 10.1136/gutjnl-2012-302084
    1. Malfertheiner P., Mégraud F., O’Morain C., Bell D., Porro B. G., Deltenre al. (1997). Current European concepts in the management of Helicobacter pylori infection – the Maastricht Consensus Report. Eur. J. Gastroenterol. Hepatol. 9 1–2.
    1. Maruyama M., Tanaka N., Kubota D., Miyajima M., Kimura T., Tokutake K., et al. (2017). Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can. J. Gastroenterol. Hepatol. 2017:4385161. 10.1155/2017/4385161
    1. McColl K. E. L. (2012). Helicobacter pylori infection: options for testing and treatment. Gastroenterol. Hepatol. 8 621–623.
    1. Megraud F., Coenen S., Versporten A., Kist M., Lopez-Brea M., Hirschl A. M., et al. (2013). Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62 34–42. 10.1136/gutjnl-2012-302254
    1. Murakami K., Sakurai Y., Shiino M., Funao N., Nishimura A., Asaka M. (2016). Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 65 1439–1446. 10.1136/gutjnl-2015-311304
    1. Ozaki H., Harada S., Takeuchi T., Kawaguchi S., Takahashi Y., Kojima Y., et al. (2018). Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion 97 212–218. 10.1159/000485097
    1. Saito Y., Konno K., Sato M., Nakano M., Kato Y., Saito H., et al. (2019). Vonoprazan-based third-line therapy has a higher eradication rate against Sitafloxacin-resistant Helicobacter pylori. Cancers 11:116. 10.3390/cancers11010116
    1. Sakurai K., Suda H., Ido Y., Takeichi T., Okuda A., Hasuda K., et al. (2017). Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J. Gastroenterol. 23 668–675. 10.3748/wjg.v23.i4.668
    1. Sheu B. S., Wu M. S., Chiu C. T., Lo J. C., Wu D. C., Liou J. M., et al. (2017). Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 22:e12368. 10.1111/hel.12368
    1. Sue S., Kuwashima H., Iwata Y., Oka H., Arima I., Fukuchi T., et al. (2017). The Superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study on helicobacter pylori eradication. Intern. Med. 56 1277–1285. 10.2169/internalmedicine.56.7833
    1. Sue S., Shibata W., Sasaki T., Kaneko H., Irie K., Kondo M., et al. (2018). Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J. Gastroenterol. Hepatol. 10.1111/jgh.14456 [Epub ahead of print].
    1. Sugano K., Tack J., Kuipers E. J., Graham D. Y., El-Omar E. M., Miura S., et al. (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut 64 1353–1367. 10.1136/gutjnl-2015-309252
    1. Sugimoto M., Yamaoka Y. (2018). Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Front. Pharmacol. 9:1560. 10.3389/fphar.2018.01560
    1. Suzuki H., Hideki M. (2018). World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J. Gastroenterol. 53 354–361. 10.1007/s00535-017-1407-1
    1. Tai W.-C., Liang C.-M., Kuo C.-M., Huang P.-Y., Wu C.-K., Yang S.-C., et al. (2019). A 14 day esomeprazole-and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J. Antimicrob. Chemother. 10.1093/jac/dkz046 [Epub ahead of print].
    1. Yamada S., Kawakami T., Nakatsugawa Y., Suzuki T., Fujii H., Tomatsuri N., et al. (2016). Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J. Gastrointest. Pharmacol. Ther. 7 550–555. 10.4292/wjgpt.v7.i4.550
    1. Zagari R. M., Romano M., Ojetti V., Stockbrugger R., Gullini S., Annibale B., et al. (2015). Guidelines for the management of Helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig. Liver Dis. 47 903–912. 10.1016/j.dld.2015.06.010
    1. Zullo A., Hassan C., De Francesco V., Repici A., Manta R., Tomao S., et al. (2014). Helicobacter pylori and functional dyspepsia: an unsolved issue? World J. Gastroenterol. 20 8957–8963. 10.3748/wjg.v20.i27.8957

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다